MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns

Core Viewpoint - MediPharm Labs Corp. announces the resignation of Shelley Potts from the Board of Directors and the reappointment of Michael Bumby, highlighting a shift in leadership aimed at supporting the company's strategic priorities in the pharmaceutical cannabinoid sector [1][3]. Group 1: Leadership Changes - Shelley Potts will step down from the Board effective December 31, 2025, after contributing to the company's growth since 2020 [1][3]. - Michael Bumby, who previously served on the Board and was CFO at VIVO Cannabis Inc., will rejoin the Board effective January 1, 2026, bringing extensive experience in finance and governance [1][2]. Group 2: Company Background - MediPharm Labs, founded in 2015, specializes in the development and manufacture of pharmaceutical-quality cannabis concentrates and active pharmaceutical ingredients, utilizing a Good Manufacturing Practices certified facility [4]. - The company received a Pharmaceutical Drug Establishment License from Health Canada in 2021, becoming the only North American company with a commercial-scale domestic GMP License for extracting multiple natural cannabinoids [5]. - In 2023, MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany, and including Harvest Medical Clinics for patient consultations [6].